Dara-KRd as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04

Phase 2 IFM 2018-04 Study Results Presented at ASCO 2022

Dr. Cyrille Touzeau Discusses Results of the Phase 2 IFM 2018-04 Study in High-Risk, Transplant-Eligible NDMM Patients 

Abstract title: 

Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04

What is the purpose of this trial? 

The Phase 2 IFM 2018-04 Study is evaluating an intensive strategy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) induction and consolidation plus double transplant in high-risk transplant-eligible newly diagnosed multiple myeloma (HR TE NDMM) patients, with a report on efficacy and safety analysis of Dara-KRd induction. 

In this video:

Dr. Cyrille Touzeau (University Hospital of Nantes—Nantes, France) discusses results of the Phase 2 IFM 2018-04 Study in HR TE NDMM patients using Dara-KRd as induction therapy plus double transplant.

Conclusion:

Dara-KRD as induction prior to ASCT is safe and allows deep responses in TE NDMM patients with high-risk cytogenetic profile. IFM 2018-04 study is ongoing and longer follow-up is needed to evaluate safety and efficacy of the overall strategy with Dara-KRD induction and consolidation plus double transplant in this subset of high-risk patients. 

Clinical trial information: NCT03606577

Subheader
EHA 2022
Video
IMF TV Blog Category

Doctor Bio:

Dr. Cyrille Touzeau is a hematologist in the Hematology Department from the University Hospital of Nantes, France. He specializes in clinical hematology, with a particular focus on multiple myeloma and its treatment. His PhD was mainly focused on the activity of BH3 mimetics in multiple myeloma. Dr. Touzeau is currently a member of the Intergroupe Francophone du Myélome (IFM). Dr. Touzeau published more than 60 peer‐reviewed publications dedicated to multiple myeloma.

with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology

 


Source URL: https://www.myeloma.org/videos/dara-krd-induction-therapy-high-risk-transplant-eligible-patients-newly-diagnosed-myeloma